# Telix Pharmaceuticals Ltd (TLX)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/telix-pharmaceuticals-ltd/ JSON: https://steadybase.io/company/telix-pharmaceuticals-ltd.json Checked Nov 21, 2026. Latest filing read: Mar 20, 2026.

## Company

- Legal name: Telix Pharmaceuticals Ltd
- Ticker: TLX, TLPPF (Nasdaq, OTC)
- SEC CIK: 0002007191
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: North Melbourne, C3
- Fiscal year ends: December 31
- SEC filer category: Large accelerated filer
- Website: telixpharma.com
- LinkedIn: https://www.linkedin.com/company/telixpharma

## Key facts

- Revenue: $803.8M for the fiscal year ended Dec 31, 2025 (20-F filed Feb 20, 2026). Source: https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/0001628280-26-009943-index.html
- Operating income: $29.8M for the fiscal year ended Dec 31, 2025 (20-F filed Feb 20, 2026). Source: https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/0001628280-26-009943-index.html
- Net income: -$7.1M for the fiscal year ended Dec 31, 2025 (20-F filed Feb 20, 2026). Source: https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/0001628280-26-009943-index.html
- Shares outstanding: 338,777,049 as of Dec 31, 2025 (20-F/A filed Mar 20, 2026). Source: https://www.sec.gov/Archives/edgar/data/2007191/000114036126010554/0001140361-26-010554-index.html
- Auditor: Pricewaterhousecoopers, Melbourne, Australia, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/tlx-20251231.htm

## Business

Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease. Page 4 29 Telix ASX disclosure September 1, 2026.

Source: Press release "About" paragraph, https://www.sec.gov/Archives/edgar/data/2007191/000162828026066581/a20261021q32026businessu.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income |
|---|---|---|---|
| Dec 31, 2025 | $803.8M | $29.8M | -$7.1M |
| Dec 31, 2024 | $516.6M | $55.2M | $33.7M |
| Dec 31, 2023 | $333.0M | $11.0M | $4.2M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/telix-pharmaceuticals-ltd.json

## Officers and directors

- Christian Behrenbruch, MD & Group CEO. Source: Form 4 filed May 6, 2026, https://www.sec.gov/Archives/edgar/data/2007191/000162828026031608/0001628280-26-031608-index.htm
- Darren Charlton Smith, Group Chief Financial Officer. Source: Form 4 filed Sep 14, 2026, https://www.sec.gov/Archives/edgar/data/2007191/000162828026061944/0001628280-26-061944-index.htm
- Darren Joel Patti, Group Chief Operating Officer. Source: Form 3 filed Apr 1, 2026, https://www.sec.gov/Archives/edgar/data/2007191/000162828026022569/0001628280-26-022569-index.htm
- David Norman Cade, Group Chief Medical Officer. Source: Form 3 filed Apr 1, 2026, https://www.sec.gov/Archives/edgar/data/2007191/000162828026022572/0001628280-26-022572-index.htm

## Insider trades (Form 4)

- Sep 7, 2026: Darren Charlton Smith (Group Chief Financial Officer) bought 2,071 shares, about $20,006. Source: https://www.sec.gov/Archives/edgar/data/2007191/000162828026061944/0001628280-26-061944-index.htm
- Apr 29, 2026: Christian Behrenbruch (MD & Group CEO) bought 67,935 shares, about $996,738. Source: https://www.sec.gov/Archives/edgar/data/2007191/000162828026031608/0001628280-26-031608-index.htm

## Latest filings

- 20f filed Feb 20, 2026: https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/tlx-20251231.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/

